Current state of Ebola virus vaccines: A snapshot
Ad26, human adenovirus serotype 26; cAd3, chimpanzee adenovirus serotype 3; EBOV, Ebola virus (Zaire ebolavirus); EBOZ, Ebolavirus-Zaire species; EMA, European Medicines Agency; FDA, US Federal Drug Administration; GP, glycoprotein; i.u., infectious unit; MARV, Marburg virus; NIAID, National Immunol...
Gespeichert in:
| Veröffentlicht in: | PLoS pathogens 2021-12, Vol.17 (12), p.e1010078-e1010078 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e1010078 |
|---|---|
| container_issue | 12 |
| container_start_page | e1010078 |
| container_title | PLoS pathogens |
| container_volume | 17 |
| creator | Woolsey, Courtney Geisbert, Thomas W |
| description | Ad26, human adenovirus serotype 26; cAd3, chimpanzee adenovirus serotype 3; EBOV, Ebola virus (Zaire ebolavirus); EBOZ, Ebolavirus-Zaire species; EMA, European Medicines Agency; FDA, US Federal Drug Administration; GP, glycoprotein; i.u., infectious unit; MARV, Marburg virus; NIAID, National Immunology Allergy and Infectious Disease; NP, nucleoprotein; PHAC, Public Health Agency of Canada; rVSV, recombinant vesicular stomatitis virus; SUDV, Sudan virus; TAFV, Taï Forest virus; ZEBOV, Zaire ebolavirus. https://doi.org/10.1371/journal.ppat.1010078.g001 [Figure omitted. Advantages and disadvantages of post-Phase I clinical trial vaccines for EBOV disease. https://doi.org/10.1371/journal.ppat.1010078.t001 Ervebo (rVSV-EBOV; V920) Ervebo is a live-attenuated, replication-competent, single-dose vaccine originally developed and shown to completely protect nonhuman primates (NHPs) by scientists at the Public Health Agency of Canada and the US Army [10]. According to preliminary results, the vaccine was 97.5% effective at stopping EBOV transmission compared to no vaccination [4]. [...]this preventive 2-dose regimen is not suitable for an outbreak response where immediate protection is necessary. |
| doi_str_mv | 10.1371/journal.ppat.1010078 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2620153425</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A688939603</galeid><doaj_id>oai_doaj_org_article_379aaa22eb2f43a8be7270f74e3cc229</doaj_id><sourcerecordid>A688939603</sourcerecordid><originalsourceid>FETCH-LOGICAL-c661t-42f57db418ce0d91da7719bec5a6faecf42b22f3a73045188479a3a9e2fb32783</originalsourceid><addsrcrecordid>eNqVkk2P0zAQhiMEYpeFf4AgEhc4tNgeJ3Y4IFXVApVWIPFxtiaO3XWVxsVOKvj3ODS72qC9IB9sjZ95Z97RZNlzSpYUBH2780PosF0eDtgvKaGECPkgO6dFAQsBgj-88z7LnsS4I4RToOXj7Ay4lExwep7R9RCC6fo89tib3Nv8svYt5kcXhpgfUWvXmfguX-Wxw0O89v3T7JHFNppn032R_fhw-X39aXH15eNmvbpa6LKk_YIzW4im5lRqQ5qKNigErWqjCywtGm05qxmzgAIIL6iUXFQIWBlma2BCwkX28qR7aH1Uk9uoWMkILYCzIhGbE9F43KlDcHsMv5VHp_4GfNgqDL3TrVGQxBEZMzWzHFDWRjBBrOAGtGasSlrvp2pDvTeNTiMJ2M5E5z-du1Zbf1SyLCqAsd3Xk0DwPwcTe7V3UZu2xc74YeybyAKAViKhr_5B73c3UVtMBlxnfaqrR1G1KqWsoCoJJGp5D5VOY_ZO-85Yl-KzhDezhMT05le_xSFGtfn29T_Yz3OWn1gdfIzB2NvZUaLGhb0xqcaFVdPCprQXd-d-m3SzofAHWzrkjQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2620153425</pqid></control><display><type>article</type><title>Current state of Ebola virus vaccines: A snapshot</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Woolsey, Courtney ; Geisbert, Thomas W</creator><contributor>Dutch, Rebecca Ellis</contributor><creatorcontrib>Woolsey, Courtney ; Geisbert, Thomas W ; Dutch, Rebecca Ellis</creatorcontrib><description>Ad26, human adenovirus serotype 26; cAd3, chimpanzee adenovirus serotype 3; EBOV, Ebola virus (Zaire ebolavirus); EBOZ, Ebolavirus-Zaire species; EMA, European Medicines Agency; FDA, US Federal Drug Administration; GP, glycoprotein; i.u., infectious unit; MARV, Marburg virus; NIAID, National Immunology Allergy and Infectious Disease; NP, nucleoprotein; PHAC, Public Health Agency of Canada; rVSV, recombinant vesicular stomatitis virus; SUDV, Sudan virus; TAFV, Taï Forest virus; ZEBOV, Zaire ebolavirus. https://doi.org/10.1371/journal.ppat.1010078.g001 [Figure omitted. Advantages and disadvantages of post-Phase I clinical trial vaccines for EBOV disease. https://doi.org/10.1371/journal.ppat.1010078.t001 Ervebo (rVSV-EBOV; V920) Ervebo is a live-attenuated, replication-competent, single-dose vaccine originally developed and shown to completely protect nonhuman primates (NHPs) by scientists at the Public Health Agency of Canada and the US Army [10]. According to preliminary results, the vaccine was 97.5% effective at stopping EBOV transmission compared to no vaccination [4]. [...]this preventive 2-dose regimen is not suitable for an outbreak response where immediate protection is necessary.</description><identifier>ISSN: 1553-7374</identifier><identifier>ISSN: 1553-7366</identifier><identifier>EISSN: 1553-7374</identifier><identifier>DOI: 10.1371/journal.ppat.1010078</identifier><identifier>PMID: 34882741</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adenoviridae ; Adenoviruses ; Allergies ; Antigens ; Biology and life sciences ; Clinical trials ; Control ; Disadvantages ; Distribution ; Drug dosages ; Ebola Vaccines ; Ebola virus ; Ebolavirus ; Epidemics ; Filoviridae ; Glycoproteins ; Hemorrhagic Fever, Ebola - prevention & control ; Humans ; Hypersensitivity ; Immunology ; Infectious diseases ; Medicine and Health Sciences ; Pearls ; Pest outbreaks ; Population ; Proteins ; Public health ; Stomatitis ; Vaccines ; Varieties ; Vectors (Biology) ; Viral diseases ; Viruses</subject><ispartof>PLoS pathogens, 2021-12, Vol.17 (12), p.e1010078-e1010078</ispartof><rights>COPYRIGHT 2021 Public Library of Science</rights><rights>2021 Woolsey, Geisbert. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Woolsey, Geisbert 2021 Woolsey, Geisbert</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c661t-42f57db418ce0d91da7719bec5a6faecf42b22f3a73045188479a3a9e2fb32783</citedby><cites>FETCH-LOGICAL-c661t-42f57db418ce0d91da7719bec5a6faecf42b22f3a73045188479a3a9e2fb32783</cites><orcidid>0000-0003-0858-1877 ; 0000-0003-3389-0137</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8659338/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8659338/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2100,2926,23864,27922,27923,53789,53791,79370,79371</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34882741$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Dutch, Rebecca Ellis</contributor><creatorcontrib>Woolsey, Courtney</creatorcontrib><creatorcontrib>Geisbert, Thomas W</creatorcontrib><title>Current state of Ebola virus vaccines: A snapshot</title><title>PLoS pathogens</title><addtitle>PLoS Pathog</addtitle><description>Ad26, human adenovirus serotype 26; cAd3, chimpanzee adenovirus serotype 3; EBOV, Ebola virus (Zaire ebolavirus); EBOZ, Ebolavirus-Zaire species; EMA, European Medicines Agency; FDA, US Federal Drug Administration; GP, glycoprotein; i.u., infectious unit; MARV, Marburg virus; NIAID, National Immunology Allergy and Infectious Disease; NP, nucleoprotein; PHAC, Public Health Agency of Canada; rVSV, recombinant vesicular stomatitis virus; SUDV, Sudan virus; TAFV, Taï Forest virus; ZEBOV, Zaire ebolavirus. https://doi.org/10.1371/journal.ppat.1010078.g001 [Figure omitted. Advantages and disadvantages of post-Phase I clinical trial vaccines for EBOV disease. https://doi.org/10.1371/journal.ppat.1010078.t001 Ervebo (rVSV-EBOV; V920) Ervebo is a live-attenuated, replication-competent, single-dose vaccine originally developed and shown to completely protect nonhuman primates (NHPs) by scientists at the Public Health Agency of Canada and the US Army [10]. According to preliminary results, the vaccine was 97.5% effective at stopping EBOV transmission compared to no vaccination [4]. [...]this preventive 2-dose regimen is not suitable for an outbreak response where immediate protection is necessary.</description><subject>Adenoviridae</subject><subject>Adenoviruses</subject><subject>Allergies</subject><subject>Antigens</subject><subject>Biology and life sciences</subject><subject>Clinical trials</subject><subject>Control</subject><subject>Disadvantages</subject><subject>Distribution</subject><subject>Drug dosages</subject><subject>Ebola Vaccines</subject><subject>Ebola virus</subject><subject>Ebolavirus</subject><subject>Epidemics</subject><subject>Filoviridae</subject><subject>Glycoproteins</subject><subject>Hemorrhagic Fever, Ebola - prevention & control</subject><subject>Humans</subject><subject>Hypersensitivity</subject><subject>Immunology</subject><subject>Infectious diseases</subject><subject>Medicine and Health Sciences</subject><subject>Pearls</subject><subject>Pest outbreaks</subject><subject>Population</subject><subject>Proteins</subject><subject>Public health</subject><subject>Stomatitis</subject><subject>Vaccines</subject><subject>Varieties</subject><subject>Vectors (Biology)</subject><subject>Viral diseases</subject><subject>Viruses</subject><issn>1553-7374</issn><issn>1553-7366</issn><issn>1553-7374</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqVkk2P0zAQhiMEYpeFf4AgEhc4tNgeJ3Y4IFXVApVWIPFxtiaO3XWVxsVOKvj3ODS72qC9IB9sjZ95Z97RZNlzSpYUBH2780PosF0eDtgvKaGECPkgO6dFAQsBgj-88z7LnsS4I4RToOXj7Ay4lExwep7R9RCC6fo89tib3Nv8svYt5kcXhpgfUWvXmfguX-Wxw0O89v3T7JHFNppn032R_fhw-X39aXH15eNmvbpa6LKk_YIzW4im5lRqQ5qKNigErWqjCywtGm05qxmzgAIIL6iUXFQIWBlma2BCwkX28qR7aH1Uk9uoWMkILYCzIhGbE9F43KlDcHsMv5VHp_4GfNgqDL3TrVGQxBEZMzWzHFDWRjBBrOAGtGasSlrvp2pDvTeNTiMJ2M5E5z-du1Zbf1SyLCqAsd3Xk0DwPwcTe7V3UZu2xc74YeybyAKAViKhr_5B73c3UVtMBlxnfaqrR1G1KqWsoCoJJGp5D5VOY_ZO-85Yl-KzhDezhMT05le_xSFGtfn29T_Yz3OWn1gdfIzB2NvZUaLGhb0xqcaFVdPCprQXd-d-m3SzofAHWzrkjQ</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Woolsey, Courtney</creator><creator>Geisbert, Thomas W</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISN</scope><scope>ISR</scope><scope>3V.</scope><scope>7QL</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-0858-1877</orcidid><orcidid>https://orcid.org/0000-0003-3389-0137</orcidid></search><sort><creationdate>20211201</creationdate><title>Current state of Ebola virus vaccines: A snapshot</title><author>Woolsey, Courtney ; Geisbert, Thomas W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c661t-42f57db418ce0d91da7719bec5a6faecf42b22f3a73045188479a3a9e2fb32783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adenoviridae</topic><topic>Adenoviruses</topic><topic>Allergies</topic><topic>Antigens</topic><topic>Biology and life sciences</topic><topic>Clinical trials</topic><topic>Control</topic><topic>Disadvantages</topic><topic>Distribution</topic><topic>Drug dosages</topic><topic>Ebola Vaccines</topic><topic>Ebola virus</topic><topic>Ebolavirus</topic><topic>Epidemics</topic><topic>Filoviridae</topic><topic>Glycoproteins</topic><topic>Hemorrhagic Fever, Ebola - prevention & control</topic><topic>Humans</topic><topic>Hypersensitivity</topic><topic>Immunology</topic><topic>Infectious diseases</topic><topic>Medicine and Health Sciences</topic><topic>Pearls</topic><topic>Pest outbreaks</topic><topic>Population</topic><topic>Proteins</topic><topic>Public health</topic><topic>Stomatitis</topic><topic>Vaccines</topic><topic>Varieties</topic><topic>Vectors (Biology)</topic><topic>Viral diseases</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Woolsey, Courtney</creatorcontrib><creatorcontrib>Geisbert, Thomas W</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Canada</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PLoS pathogens</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Woolsey, Courtney</au><au>Geisbert, Thomas W</au><au>Dutch, Rebecca Ellis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current state of Ebola virus vaccines: A snapshot</atitle><jtitle>PLoS pathogens</jtitle><addtitle>PLoS Pathog</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>17</volume><issue>12</issue><spage>e1010078</spage><epage>e1010078</epage><pages>e1010078-e1010078</pages><issn>1553-7374</issn><issn>1553-7366</issn><eissn>1553-7374</eissn><abstract>Ad26, human adenovirus serotype 26; cAd3, chimpanzee adenovirus serotype 3; EBOV, Ebola virus (Zaire ebolavirus); EBOZ, Ebolavirus-Zaire species; EMA, European Medicines Agency; FDA, US Federal Drug Administration; GP, glycoprotein; i.u., infectious unit; MARV, Marburg virus; NIAID, National Immunology Allergy and Infectious Disease; NP, nucleoprotein; PHAC, Public Health Agency of Canada; rVSV, recombinant vesicular stomatitis virus; SUDV, Sudan virus; TAFV, Taï Forest virus; ZEBOV, Zaire ebolavirus. https://doi.org/10.1371/journal.ppat.1010078.g001 [Figure omitted. Advantages and disadvantages of post-Phase I clinical trial vaccines for EBOV disease. https://doi.org/10.1371/journal.ppat.1010078.t001 Ervebo (rVSV-EBOV; V920) Ervebo is a live-attenuated, replication-competent, single-dose vaccine originally developed and shown to completely protect nonhuman primates (NHPs) by scientists at the Public Health Agency of Canada and the US Army [10]. According to preliminary results, the vaccine was 97.5% effective at stopping EBOV transmission compared to no vaccination [4]. [...]this preventive 2-dose regimen is not suitable for an outbreak response where immediate protection is necessary.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>34882741</pmid><doi>10.1371/journal.ppat.1010078</doi><orcidid>https://orcid.org/0000-0003-0858-1877</orcidid><orcidid>https://orcid.org/0000-0003-3389-0137</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1553-7374 |
| ispartof | PLoS pathogens, 2021-12, Vol.17 (12), p.e1010078-e1010078 |
| issn | 1553-7374 1553-7366 1553-7374 |
| language | eng |
| recordid | cdi_plos_journals_2620153425 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central Open Access; Public Library of Science (PLoS) Journals Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adenoviridae Adenoviruses Allergies Antigens Biology and life sciences Clinical trials Control Disadvantages Distribution Drug dosages Ebola Vaccines Ebola virus Ebolavirus Epidemics Filoviridae Glycoproteins Hemorrhagic Fever, Ebola - prevention & control Humans Hypersensitivity Immunology Infectious diseases Medicine and Health Sciences Pearls Pest outbreaks Population Proteins Public health Stomatitis Vaccines Varieties Vectors (Biology) Viral diseases Viruses |
| title | Current state of Ebola virus vaccines: A snapshot |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T02%3A19%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20state%20of%20Ebola%20virus%20vaccines:%20A%20snapshot&rft.jtitle=PLoS%20pathogens&rft.au=Woolsey,%20Courtney&rft.date=2021-12-01&rft.volume=17&rft.issue=12&rft.spage=e1010078&rft.epage=e1010078&rft.pages=e1010078-e1010078&rft.issn=1553-7374&rft.eissn=1553-7374&rft_id=info:doi/10.1371/journal.ppat.1010078&rft_dat=%3Cgale_plos_%3EA688939603%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2620153425&rft_id=info:pmid/34882741&rft_galeid=A688939603&rft_doaj_id=oai_doaj_org_article_379aaa22eb2f43a8be7270f74e3cc229&rfr_iscdi=true |